APA (7th ed.) Citation

Yap, Y., Im, S., Lu, Y., Azim, H., Eralp, Y., Kanakasetty, G., . . . El Saghir, N. (2023). 57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial. Annals of Oncology, 34, S1488. https://doi.org/10.1016/j.annonc.2023.10.192

Chicago Style (17th ed.) Citation

Yap, Y-S, et al. "57MO First-line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) Vs Combination Chemotherapy (combo CT) in HR+/HER2− Advanced Breast Cancer (ABC): A Post Hoc Analysis of Asian and Non-Asian Patients (pts) from the Phase II RIGHT Choice Trial." Annals of Oncology 34 (2023): S1488. https://doi.org/10.1016/j.annonc.2023.10.192.

MLA (9th ed.) Citation

Yap, Y-S, et al. "57MO First-line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) Vs Combination Chemotherapy (combo CT) in HR+/HER2− Advanced Breast Cancer (ABC): A Post Hoc Analysis of Asian and Non-Asian Patients (pts) from the Phase II RIGHT Choice Trial." Annals of Oncology, vol. 34, 2023, p. S1488, https://doi.org/10.1016/j.annonc.2023.10.192.